Actinium Pharmaceuticals, Inc. [NYSE: ATNM] shares went lower by -6.37% from its previous closing of $0.25, now trading at the price of $0.23, also adding -0.02 points. Is ATNM stock a buy or should you stay away?

The stock had a rather active trading session with the latest closing, by far recording 2.01 million contracts. Compared to the average trading volume of ATNM shares, the company saw a far better performance. Moreover, the stock has a 162.88M float and a -14.23% run over in the last seven days. ATNM share price has been hovering between $0.71 and $0.19 lately, and is definitely worthy of attention.

Actinium Pharmaceuticals, Inc. [NYSE:ATNM]: Analyst Rating and Earnings

Its stock price has been found in the range of 0.19 to 0.71. This is compared to its latest closing price of $0.25.

Keep your eyes peeled for this company’s upcoming financial results publication, which is slated for Tue 17 Mar (In 50 Days).

Fundamental Analysis of Actinium Pharmaceuticals, Inc. [ATNM]

Turning to investigate this organization’s capital structure, Actinium Pharmaceuticals, Inc. [ATNM] has generated a Total Debt to Total Equity ratio of 2.98. Similarly, its Total Debt to Total Capital is 2.89, while its Total Debt to Total Assets stands at 1.76.

What about valuation? This company’s Enterprise Value to EBITDA is -1.10. Total Debt to Enterprise Value stands at 0.01. Actinium Pharmaceuticals, Inc. [ATNM] has a Price to Book Ratio of 5.08.

This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.36 and its Current Ratio is 2.36. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Actinium Pharmaceuticals, Inc. [ATNM] has 163.34M shares outstanding, amounting to a total market cap of $38.38M. Its stock price has been found in the range of 0.19 to 0.71. At its current price, it has moved down by -66.83% from its 52-week high, and it has moved up 23.68% from its 52-week low.

This stock’s Beta value is currently 1.88, which indicates that it is 7.59% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 47.01. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Actinium Pharmaceuticals, Inc. [ATNM] a Reliable Buy?

Shares of Actinium Pharmaceuticals, Inc. [ATNM], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.